

EPIQ GRAND ROUNDS

Session 19

Erythropoietin as a Neuroprotective Agent in Preterm and Term Neonates

Objectives:

- Discuss the reasons erythropoietin might or might not be neuroprotective for neonates.
- Understand important preclinical work that should be done prior to clinical trials.
- Discuss factors that affect study outcomes in clinical trials.

Presented by:

Dr. Sandra E. Juul



Professor Sandra Juul, MD, PhD is a Professor of Pediatrics and Neuroscience at Seattle Children's Hospital and the University of Washington. Dr. Juul leads a translational neonatal neuroscience research program and has been continuously NIH funded for over 25 years. The focus of her research is to identify new therapeutic approaches to neonatal brain injury, determine whether they are safe and effective, and if so, bring these new treatments from the laboratory to the bedside. Dr. Juul has been principal investigator on two large phase III trials to evaluate Erythropoietin as a neuroprotective agent and is currently leading a trial to decrease transfusions while maintaining iron sufficiency in preterm infants. She is now Director of the Institute on Human Development and Disability as well as the Intellectual and Developmental Disabilities Research Center (IDDRC), which are dedicated to enhancing the lives of individuals with developmental disabilities.

WEDNESDAY OCTOBER 23RD, 2024

Length: 1 hour

9:00 AM PDT / 10:00 AM MDT / 11:00 AM CDT / 12:00 PM EDT / 1:00 PM ADT / 1:30 PM NDT

Join Zoom Webinar

<https://sinaihealth.zoom.us/j/98774418982?pwd=G2AGAR4ACtEKfYaMccsZlddheSBJ5c.1>



Webinar ID: 987 7441 8982
Passcode: EPIQ123

